Drug delivery platform for the local biological therapy of ocular inflammation
Description of the granted funding
Inflammation of the eye (also called uveitis) affects young adults aged 20-50 (sometimes also children) and can lead to blindness. Biological therapeutics are very effective in the treatment of ocular inflammation, however they must be administered systemically and can cause serious side-effects, including cancer. This project aims to develop a novel treatment that allows the safe and effective delivery of biological therapeutics directly to the eye. This local delivery is achieved by using short pieces of RNA called aptamers that can target the biological therapeutics to the inflammation site inside the eye.The method used to find these aptamers is called SELEX. Aptamer-targeted biological therapeutics are also embedded inside hydrogels, this allows their prolonged release and thus decreases the administration frequency. Overall, this project will develop a safer and more comfortable treatment for patients with ocular inflammation and thus decrease their risk of getting blind.
Show moreStarting year
2020
End year
2026
Granted funding
Related funding decisions
336280
Research costs of Academy Research Fellows(2020)
231 806 €
Funder
Research Council of Finland
Funding instrument
Academy research fellows
Other information
Funding decision number
333301
Fields of science
Pharmacy
Research fields
Farmasia
Identified topics
eyes, eye diseases